APL-1202

DRUG3 trials

Sponsors

Asieris Pharmaceutical Technologies Co., Ltd., Jiangsu Yahong Meditech Co., Ltd aka Asieris, Syneos Health

Conditions

Healthy VolunteersNon-Muscle Invasive Bladder Cancer (NMIBC)Non-muscle Invasive Bladder Cancer

Phase 1

Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment

CompletedNCT03672240

Asieris Pharmaceutical Technologies Co., Ltd.Non-Muscle Invasive Bladder Cancer (NMIBC)

Start: 2018-11-30End: 2020-06-30Updated: 2020-07-20

A Study of APL-1501 Extended Release Capsules Compared to APL-1202 Immediate Release Tablets in Healthy Volunteers

TerminatedNCT06435039

Syneos HealthHealthy Volunteers

Start: 2024-06-21End: 2024-07-16Updated: 2025-01-31

Phase 3

A Phase 3 Study to Evaluate the Safety and Efficacy of APL-1202 as a Single-agent Oral Treatment Versus Intravesical Instillation of Epirubicin Hydrochloride in naïve Intermediate-risk NMIBC Patients

Jiangsu Yahong Meditech Co., Ltd aka AsierisNon-muscle Invasive Bladder Cancer

Start: 2021-09-29End: 2025-12-31Target: 800Updated: 2022-02-22

Related Papers

Phase Ib study: APL-1202 (APL) in combination with Bacillus Calmette-Guerin (BCG) in recurrent non-muscle invasive bladder cancer (NMIBC).

Journal of Clinical Oncology2020-05-204 citations